4 completed, 3 recruiting, 2 terminated, 2 unknown. 15 Phase 2, 3 Phase 1, 1 Phase 3.
Follow Allogeneic Stem Cell Transplantation: new trials by email Literature Review of Allogeneic Stem Cell Transplantation trials Research Report on Allogeneic Stem Cell Transplantation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention Cyclophosphamide (primary intervention for GVHD prophylaxis) - Graft-versus-Host Disease (GVHD), Hematologic Malignancies | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 41 | 2026-03-09 | 2026-04-03 |
| Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant CARTemis-1 - Multiple Myeloma, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Not yet recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 25 | 2024-12-30 | 2024-05-14 |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation ASTX727, Donor Lymphocyte Infusion - Allogeneic Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-07-01 | 2026-05-15 | |
| CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR - CMV, Allogeneic Stem Cell Transplantation | Phase 2 | Recruiting | University of California, Irvine | 50 | 2024-06-27 | 2026-07-21 |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Fludarabine, Melphalan, Total Body Irradiation - Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation | Phase 2 | Recruiting | University of California, Irvine | 60 | 2023-09-11 | 2026-02-02 |
| Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant Xylitol, Placebo - Allogeneic Stem Cell Transplantation | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 256 | 2023-04-04 | 2026-11-02 |
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant Siremadlin - Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2023-02-23 | 2025-05-16 |
| Bisantrene for Relapsed /Refractory AML Bisantrene - Acute Myelogenous Leukemia, Allogeneic Stem Cell Transplantation | Phase 2 | Completed | Sheba Medical Center | 10 | 2019-07-18 | 2020-08-07 |
| CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia CLAGE-FluBu - Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation | Phase 2 | Completed | Shanghai Jiao Tong University School of Medicine | 18 | 2018-08-01 | 2023-08-15 |
| Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Ruxolitinib - Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission | Phase 2 | Active not recruiting | Massachusetts General Hospital | 64 | 2017-11-03 | 2026-03-27 |
| Bortezomib to Treat Significant Complication of HSCT Bortezomib - Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s) | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 4 | 2012-07-01 | 2016-10-24 |
| Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation Lymphopheresis, CMV specific lymphocyte infusion, Peripheral blood for CMV DNA PCR - CMV Reactivation, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Withdrawn | Imperial College London | 2011-04-01 | 2015-06-08 | |
| Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation itraconazole - Hematological Diseases, Allogeneic Stem Cell Transplantation | Phase 2 | Unknown | Guangzhou General Hospital of Guangzhou Military Command | 120 | 2009-05-01 | 2010-07-26 |
| Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Budesonide/formoterol, Placebo - Bronchiolitis Obliterans, Allogeneic Stem Cell Transplantation | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 32 | 2008-06-01 | 2012-09-07 |
| Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT) Levofloxacin - Malignancy, Allogeneic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Charite University, Berlin, Germany | 2007-11-30 |
Hematologic Neoplasms (4) · Leukemia, Myeloid, Acute (3) · Bronchiolitis Obliterans (1) · Cytopenia (1) · Gingivitis (1) · Graft vs Host Disease (1) · Hematologic Diseases (1) · Leukemia (1) · Lung Diseases, Obstructive (1) · Mucositis (1) · Multiple Myeloma (1) · Neoplasms (1) · Plaque, Amyloid (1) · Sepsis (1)
Hemic and Lymphatic Diseases (10) · Hematologic Diseases (9) · Neoplasms (8) · Neoplasms by Histologic Type (5) · Neoplasms by Site (4) · Leukemia (3) · Leukemia, Myeloid (3) · Immune System Diseases (2) · Blood Protein Disorders (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchitis (1) · Cardiovascular Diseases (1) · Digestive System Diseases (1) · Gastroenteritis (1)
Blood Chemical Analysis (1) · Bortezomib (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Cyclophosphamide (1) · Itraconazole (1) · Leukapheresis (1) · Levofloxacin (1) · Melphalan (1) · Mycophenolic Acid (1) · Tacrolimus (1) · Whole-Body Irradiation (1) · Xylitol (1) · bisantrene (1) · decitabine and cedazuridine drug combination (1) · fludarabine (1)
Children's Hospital Medical Center, Cincinnati (2) · University of California, Irvine (2) · Assistance Publique - Hôpitaux de Paris (1) · Charite University, Berlin, Germany (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Guangzhou General Hospital of Guangzhou Military Command (1) · Imperial College London (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Milton S. Hershey Medical Center (1) · Novartis Pharmaceuticals (1) · Shanghai Jiao Tong University School of Medicine (1) · Sheba Medical Center (1)
United States (7) · China (2) · Germany (2) · Spain (2) · France (1) · Israel (1) · Italy (1) · United Kingdom (1)
Betul Oran, MD (1) · Christopher Dandoy, MD, MSc (1) · Gabriell Hobbs, MD (1) · Igor Wolfgang Blau, Dr. (1) · Jose-Antonio Perez-Simon, MD-PhD (1) · Joseph Cioccio, MD (1) · Junming Li, M.D (1) · Katy Rezvani, MD (1) · Lisa Filipovich, MD (1) · Piyanuch Kongtim, MD,PhD (1) · Stefan O. Ciurea, MD (1) · Yang Xiao, MD (1)
1UG3DE030401-01 (1)